Enzo Biochem and Sequenom Partner to Market Key Sequenom Laboratories Prenatal Testing Service

  Enzo Biochem and Sequenom Partner to Market Key Sequenom Laboratories
  Prenatal Testing Service

     Partnership Underscores Strong Integrated Life Science-Clinical Lab
                                 Capabilities

Business Wire

NEW YORK -- October 29, 2013

The Enzo Clinical Labs subsidiary of Enzo Biochem, Inc. (NYSE:ENZ) has entered
into an agreement to market in its northeast U.S. service area a proprietary
early non-invasive prenatal laboratory test (“LDT”) service, MaterniT21 PLUS
™, developed by the Sequenom Laboratories, Inc., subsidiary of Sequenom, Inc.
(NASDAQ:SQNM).

“The addition of Sequenom Laboratories’ innovative prenatal testing service
provides an important complement to our extensive menu of women’s health
diagnostic assays, and also is testament to the strong and growing
capabilities in the general and rapidly developing area of diagnostics
resulting from integration of Enzo’s Life Sciences and Clinical Labs,” said
Barry Weiner, Enzo President.

Mr. Weiner added, “Sequenom Laboratories’ testing service will be of great
value to our physician clients and their patients, providing an advanced
crucial assay to assess the potential for chromosomal abnormalities early in a
pregnancy. It also underscores our Company’s leading independent position in a
highly valuable regional market for clinical laboratory services, and our
expertise in the development and marketing of high-value esoteric testing that
provides an excellent vehicle through which we can offer this, as well as our
growing menu of ground breaking diagnostic assays.”

Sequenom Laboratories was the first to market a noninvasive prenatal
laboratory-developed test for fetal chromosomal abnormalities. The MaterniT21
PLUS test analyzes the relative amount of 21, 18, 13, as well as X and Y
chromosomal material in cell-free DNA. The test is intended for use in
pregnant women at increased risk for fetal aneuploidy, can be used as early as
10 weeks' gestation, andis run exclusively by Sequenom Center for Molecular
Medicine, doing business as Sequenom Laboratories Estimates suggest there are
about 750,000 pregnancies at high risk for fetal aneuploidy each year in the
United States.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of
clinical laboratories, life sciences and therapeutics through the development
of unique diagnostic platform technologies that provide numerous advantages
over previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products systems and services
that meet the ever-changing and rapidly growing needs of health care both
today and into the future. Underpinning Enzo Biochem’s products and
technologies is a broad and deep intellectual property portfolio, with patent
coverage across a number of key enabling technologies.

Except for historical information, the matters discussed in this news release
may be considered "forward-looking" statements within the meaning of Section
27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. Such statements include
declarations regarding the intent, belief or current expectations of the
Company and its management, including those related to cash flow, gross
margins, revenues, and expenses are dependent on a number of factors outside
of the control of the company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other expenses,
government regulations, litigations, and general business conditions. See Risk
Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2013.
Investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results. The Company
disclaims any obligations to update any forward-looking statement as a result
of developments occurring after the date of this press release.

Contact:

For Enzo Biochem, Inc.
Anreder & Company
Steven Anreder, 212-532-3232
steven.anreder@anreder.com
or
CEOcast, Inc.
Michael Wachs, 212-732-4300
mwachs@ceocast.com